Actively Recruiting
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
Led by RemeGen Co., Ltd. · Updated on 2025-11-26
312
Participants Needed
39
Research Sites
250 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective is to evaluate the safety and tolerability of RC278; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC278; and determine the recommended phase 2 dose (RP2D)， and assess the efficacy of RC278 at the RP2D dose;
CONDITIONS
Official Title
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily participate and sign informed consent
- Age between 18 and 75 years, inclusive
- ECOG performance status of 0 or 1
- Expected survival of at least 12 weeks
- At least one measurable target lesion per RECIST v1.1 imaging criteria
- Adequate bone marrow, liver, kidney, and blood clotting function
You will not qualify if you...
- Pregnant, breastfeeding, or planning pregnancy
- Presence of brain metastases
- Unresolved toxicities from prior anti-tumor therapy not recovered to Grade 1
- Known allergy or delayed hypersensitivity to components of RC278 or similar drugs
- Acute, chronic, or symptomatic infections
- Uncontrolled cardiovascular diseases
- Confirmed or suspected interstitial lung disease or severe pulmonary conditions
- History of cirrhosis classified as Child-Pugh B or C
- Active inflammatory bowel disease
- Uncontrolled diabetes with HbA1c ≥ 10%
- Recent arterial/venous thromboembolic events or stroke within 6 months
- Uncontrolled pericardial effusion, cardiac tamponade, or third-space fluid accumulation
- Active autoimmune diseases requiring systemic treatment within 2 years
- History of other invasive malignancies within 5 years or residual disease
- History of immunodeficiency or organ transplantation
- Uncontrolled psychiatric disorders
- Poor adherence or unlikely to comply with study procedures
- Any other medical condition or abnormality judged unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 39 locations
1
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Actively Recruiting
2
Fujian Cancer Hospital
Fuzhou, Fujian, China
Actively Recruiting
3
Fujian Cancer Hospital
Fuzhou, Fujian, China
Actively Recruiting
4
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Actively Recruiting
5
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Actively Recruiting
6
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
Actively Recruiting
7
Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute
Nanning, Guangxi, China
Actively Recruiting
8
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Actively Recruiting
9
Anyang Cancer Hospital
Luoyan, Henan, China
Actively Recruiting
10
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, China
Actively Recruiting
11
Nanyang Second General Hospital
Nanyang, Henan, China
Actively Recruiting
12
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
Actively Recruiting
13
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Actively Recruiting
14
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Wuhan, Hu'Nan, China
Actively Recruiting
15
Hubei Cancer Hospital
Wuhan, Hubei, China
Actively Recruiting
16
Tongji Hospital, Tongji Medical College of HUST, China
Wuhan, Hubei, China
Actively Recruiting
17
Hunan Cancer Hospital
Changsha, Hunan, China
Actively Recruiting
18
Hunan Cancer Hospital
Changsha, Hunan, China
Actively Recruiting
19
Hunan Cancer Hospital
Changsha, Hunan, China
Actively Recruiting
20
Hunan Cancer Hospital
Changsha, Hunan, China
Actively Recruiting
21
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Actively Recruiting
22
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Actively Recruiting
23
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
Actively Recruiting
24
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Actively Recruiting
25
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
Actively Recruiting
26
The first Hospital of China Medical University
Shenyang, Liaoning, China
Actively Recruiting
27
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Actively Recruiting
28
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Actively Recruiting
29
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Actively Recruiting
30
Yunnan Tumor Hospital
Kunming, Yunnan, China
Actively Recruiting
31
Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Actively Recruiting
32
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Actively Recruiting
33
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
Actively Recruiting
34
Sun Yat-sen University Cancer Center
Guangzhou, China
Actively Recruiting
35
The First Affiliated Hospital, Zhejiang University School Of Medicine
Hangzhou, China
Actively Recruiting
36
Cancer Hospital of Shandong First Medical University
Jinan, China
Actively Recruiting
37
Jinan Central Hospital
Jinan, China
Actively Recruiting
38
Shanxi Cancer Hospital
Taiyuan, China
Actively Recruiting
39
Henan Cancer Hospital
Zhengzhou, China
Actively Recruiting
Research Team
X
Xiaohong Su
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here